Atopic-dermatitis-suppressing fiber, fiber assembly and fiber product, method for using same, and method for suppressing atopic dermatitis
US-2015352141-A1 · Dec 10, 2015 · US
Use of the modified polysaccharides for heparin neutralization
US9504707B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9504707-B2 |
| Application number | US-201113642279-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 20, 2011 |
| Priority date | Apr 22, 2010 |
| Publication date | Nov 29, 2016 |
| Grant date | Nov 29, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The subject of the invention is the use of cationically modified polysaccharides, except for chitosan, for direct neutralization of heparin in blood and physiological fluids in a mammal. Cationic modification of the polysaccharides is achieved using compound containing cationic ammonium groups and/or the polysaccharides are grafted with a polymer containing amine and/or ammonium groups.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of direct neutralization of unfractionated heparin in blood and physiological fluids comprising intravenously administering to a mammal in need thereof cationically modified polysaccharides comprising hydroxypropyl cellulose grafted with N-acrylamidopropyl-N,N,N-trimethylammonium chloride. 2. The method according to claim 1 wherein the hydroxypropyl cellulose grafted with N-acrylamidopropyl-N,N,N-trimethylammonium chloride is used as an intravenous solution. 3. The method according to claim 1 wherein the mammal includes therein blood or physiological fluid obtained from a donor. 4. A method comprising: intravenously administering to a mammal in need of neutralizing anticoagulative effects of unfractionated heparin, a material including an amount of hydroxypropyl cellulose grafted with N-acrlamidopropyl-N,N,N-trimethylammonium chloride sufficient to neutralize such anticoagulative effects, wherein the hydroxypropyl cellulose grafted with N-acrylamidopropyl-N,N,N-trimethylammonium chloride directly neutralizes unfractionated heparin in the blood or physiological fluids in the mammal.
Assignees
Inventors
Classifications
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
Dextrans · CPC title
- A61K31/717Primary
Celluloses · CPC title
for osteoporosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9504707B2 cover?
- The subject of the invention is the use of cationically modified polysaccharides, except for chitosan, for direct neutralization of heparin in blood and physiological fluids in a mammal. Cationic modification of the polysaccharides is achieved using compound containing cationic ammonium groups and/or the polysaccharides are grafted with a polymer containing amine and/or ammonium groups.
- Who is the assignee on this patent?
- Nowakowska Maria, Szczubiałka Krzysztof, Kamiński Kamil, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/717. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).